Technology and products
Optimizing chemotherapeutics through improved delivery
With multiple products in clinical development, Celsion is gaining momentum and is well positioned to deliver on its primary goal to improve standard treatment options for difficult-to-treat cancers. Mono-or in combination with radiation, traditional chemotherapy has long been the mainstay in the fight against cancer. The challenge for these traditional treatment options has always been the ability to deliver a truly tumor-killing dose of the anticancer agent without increasing associated side effects. At Celsion, our goal is to develop oncology therapeutics that demonstrate a greater ability to target cancerous tumors by delivering high concentrations of known chemotherapeutics to the lesion site, maximizing efficacy and minimizing the burden of side effects caused by systemic toxicity.
Celsion's approach
At clinically achievable temperatures, anti-tumor drugs are released from Celsion's intravenously administered heat-activated liposomes. Our technology allows for the use of a variety of available focused-energy technologies that are designed to heat cancerous lesions. This approach holds the potential to deliver a greater concentration of drug, directly to the tumor, while improving the tolerability compared with conventional therapy.
Download a copy of our company brochure Innovation in oncology
Heat-activated liposome drug delivery
Through a perpetual, world-wide, exclusive development and commercialization license from Duke University, Celsion has obtained a novel, proprietary technology. This technology, lysolipid thermally-sensitive liposomes (LTSL) differentiates itself from other liposomal technologies through its unique low heat-activated release of encapsulated chemotherapeutic agents right at the cancer site. The first in a new generation of liposomes, LTSL will enable clinicians to target precisely where they want to deliver a high concentration of cancer killing drug.
First on the horizon: ThermoDox®- doxorubicin dramatically enhanced with LTSL to treat both hepatocellular carcinoma (HCC, or primary liver cancer) and recurrent chest wall (RCW) breast cancer.
First on the horizon: ThermoDox® - doxorubicin dramatically enhanced with LTSL to treat both hepatocellular carcinoma (HCC, or primary liver cancer) and recurrent chest wall (RCW) breast cancer.
More about ThermoDox heat-activated liposomal encapsulated doxorubicin